Maxygen and Aventis Pasteur Enter Strategic Alliance to Develop Improved Vaccines
Advertisement
Maxygen, Inc. (Nasdaq:MAXY) and Aventis Pasteur today announced the signing of a three-year agreement to develop improved vaccines for a specific undisclosed target.
Maxygen’s MolecularBreeding™ directed molecular evolution technologies are ideally suited to improve vaccine products in key ways, including improving immunogenicity, purity and manufacturability.
Under the terms of the agreement, Maxygen will receive license fees, full research and development funding, minimum annual royalties, and potential milestone and royalty payments on product sales. Aventis Pasteur will receive exclusive worldwide rights to commercialize the vaccines developed in the collaboration.
“The collaboration with Aventis Pasteur is an important milestone in our strategic focus to develop vaccines and protein pharmaceuticals to treat serious unmet medical needs. This is the third significant pharmaceutical partnership that we have signed this year,â€
Most read news
Other news from the department business & finance
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.